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Summary
Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement 
and high relapse burden for enteric fever, whereas the ﬂ uoroquinolone gatiﬂ oxacin is associated with rapid fever 
clearance and low relapse burden, we postulated that gatiﬂ oxacin would be superior to the cephalosporin ceftriaxone 
in treating enteric fever.
Methods We did an open-label, randomised, controlled, superiority trial at two hospitals in the Kathmandu valley, 
Nepal. Eligible participants were children (aged 2–13 years) and adult (aged 14–45 years) with criteria for suspected 
enteric fever (body temperature ≥38·0°C for ≥4 days without a focus of infection). We randomly assigned eligible 
patients (1:1) without stratiﬁ cation to 7 days of either oral gatiﬂ oxacin (10 mg/kg per day) or intravenous ceftriaxone 
(60 mg/kg up to 2 g per day for patients aged 2–13 years, or 2 g per day for patients aged ≥14 years). The randomisation 
list was computer-generated using blocks of four and six. The primary outcome was a composite of treatment failure, 
deﬁ ned as the occurrence of at least one of the following: fever clearance time of more than 7 days after treatment 
initiation; the need for rescue treatment on day 8; microbiological failure (ie, blood cultures positive for Salmonella 
enterica serotype Typhi, or Paratyphi A, B, or C) on day 8; or relapse or disease-related complications within 28 days of 
treatment initiation. We did the analyses in the modiﬁ ed intention-to-treat population, and subpopulations with 
either conﬁ rmed blood-culture positivity, or blood-culture negativity. The trial was powered to detect an increase of 
20% in the risk of failure. This trial was registered at ClinicalTrials.gov, number NCT01421693, and is now closed.
Findings Between Sept 18, 2011, and July 14, 2014, we screened 725 patients for eligibility. On July 14, 2014, the trial was 
stopped early by the data safety and monitoring board because S Typhi strains with high-level resistance to ciproﬂ oxacin 
and gatiﬂ oxacin had emerged. At this point, 239 were in the modiﬁ ed intention-to-treat population (120 assigned to 
gatiﬂ oxacin, 119 to ceftriaxone). 18 (15%) patients who received gatiﬂ oxacin had treatment failure, compared with 19 
(16%) who received ceftriaxone (hazard ratio [HR] 1·04 [95% CI 0·55–1·98]; p=0·91). In the culture-conﬁ rmed 
population, 16 (26%) of 62 patients who received gatiﬂ oxacin failed treatment, compared with four (7%) of 54 who 
received ceftriaxone (HR 0·24 [95% CI 0·08–0·73]; p=0·01). Treatment failure was associated with the emergence of 
S Typhi exhibiting resistance against ﬂ uoroquinolones, requiring the trial to be stopped. By contrast, in patients with a 
negative blood culture, only two (3%) of 58 who received gatiﬂ oxacin failed treatment versus 15 (23%) of 65 who received 
ceftriaxone (HR 7·50 [95% CI 1·71–32·80]; p=0·01). A similar number of non-serious adverse events occurred in each 
treatment group, and no serious events were reported.
Interpretation Our results suggest that ﬂ uoroquinolones should no longer be used for treatment of enteric fever in 
Nepal. Additionally, under our study conditions, ceftriaxone was suboptimum in a high proportion of patients with 
culture-negative enteric fever. Since antimicrobials, speciﬁ cally ﬂ uoroquinolones, are one of the only routinely used 
control measures for enteric fever, the assessment of novel diagnostics, new treatment options, and use of existing 
vaccines and development of next-generation vaccines are now a high priority.
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Introduction
Enteric (typhoid) fever, a systemic infection caused by the 
Salmonella enterica serovars Typhi and Paratyphi A, B, 
and C, is a leading cause of febrile disease in many 
low-income countries. 27 million new infections and 
more than 200 000 deaths are estimated to be attributable 
to enteric fever worldwide each year.1,2 In Kathmandu, the 
capital of Nepal and the setting of this study, the burden 
of enteric fever is particularly high, and is the leading 
cause of febrile bacterial disease in adults and children.3,4
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Resistance and reduced susceptibility to antimicrobials 
are the major challenges to successful treatment of 
enteric fever.5,6 We have previously reported3,7 a high 
prevalence of S Typhi and S Paratyphi A strains in Nepal 
that show resistance against the quinolone nalidixic 
acid (minimum inhibitory concentration [MIC] 
≥256 μg/mL) with a corresponding decreased 
susceptibility against ﬂ uoroquinolones such as 
ciproﬂ oxacin (MIC ≥0·125 μg/mL).3,7 Ceftriaxone, a 
parenteral, third-generation cephalosporin, is a 
common empirical therapy for febrile disease in 
endemic enteric fever locations, and is used for the 
treatment of enteric fever in south Asia and other 
regions where nalidixic acid-resistant strains 
predominate. Furthermore, ceftriaxone is also advocated 
for the treatment of travellers returning with enteric 
fever from areas of enteric fever endemicity.8,9 
Investigators for three randomised controlled trials 
have compared ﬂ uoroquinolones with ceftriaxone for 
treatment of enteric fever.10–12 Their ﬁ ndings generally 
favoured the ﬂ uoroquinolones, but the studies were 
insuﬃ  ciently powered (only 15 to 25 patients per 
treatment group) to reach signiﬁ cance and data for the 
prevalence of nalidixic acid-resistant strains were not 
reported.13
Intravenous therapy is expensive and diﬃ  cult to give 
reliably (particularly to outpatients) in most countries 
where enteric fever is endemic; therefore, eﬀ ective oral 
antimicrobials are more practical for treatment of this 
disease. Previously, we have shown that even without 
reported resistance, the oral third-generation 
cephalosporin, ceﬁ xime, did poorly in Nepalese patients 
with enteric fever—treatment failure was reported in 
26 (37%) of 70 patients receiving ceﬁ xime versus three 
(3%) of 88 patients receiving gatiﬂ oxacin.14 Conversely, we 
have also shown in Nepalese and Vietnamese children and 
adults with uncomplicated enteric fever that the fourth-
generation 8-methoxy-ﬂ uoroquinolone gatiﬂ oxacin is safe 
and eﬀ ective despite an increase in prevalence of S Typhi 
strains with reduced ciproﬂ oxacin susceptibility.14–17
Therefore, because third-generation cephalosporins 
are generally associated with slow clinical improvement 
and high relapse burden,18,19 and 7 days of oral gatiﬂ oxacin 
is associated with rapid fever clearance (≤4 days) and low 
relapse burden, we postulated that gatiﬂ oxacin is superior 
to ceftriaxone in treating enteric fever, and did a study to 
test this hypothesis.
Methods
Study design and participants
We did an open-label, randomised, controlled, superiority 
trial at Patan Hospital and the Civil Services Hospital in 
the Kathmandu valley, Nepal. The study protocol was 
reviewed and approved by the Ethics Committee of the 
Nepal Health Research Council and the Oxford Tropical 
Research Ethics Committee (UK).
We screened children aged 2–13 years and adults aged 
14–45 years with suspected enteric fever. The criteria for 
suspected enteric fever were body temperature at least 
38·0°C for 4 days or more without a focus of infection, 
as assessed by physical examination and laboratory tests, 
and as previously described.14,16,17 Patients were excluded 
if they were pregnant; had diabetes mellitus, signs of 
severe infection (eg, obtundation, shock, clinical 
jaundice, or active gastrointestinal bleeding), or a history 
of hyper sensitivity to either of the trial drugs; or had 
Research in context
Evidence before this study
We searched MEDLINE, PubMed, and Scopus without date 
restrictions for English-language articles with the search 
terms “randomized controlled trial” (“RCT” or “randomized* 
control* trial*”) AND “typhoid fever”, “enteric fever”, AND 
“ceftriaxone”. We also noted relevant articles outlined in a 
Cochrane review, and a meta-analysis, of ﬂ uoroquinolones 
versus other antimicrobials in the treatment of enteric fever. 
We identiﬁ ed 11 randomised trials that used intravenous 
ceftriaxone in one of their treatment groups. The selected 
trials had small sample sizes (ranging from 15 to 43 patients) 
and the deﬁ nitions of outcomes for the primary and 
secondary outcomes were not standardised. Three trials gave 
ceftriaxone for 7 days in one of their groups (for 73 patients), 
the same duration as in our trial, but the drug dose was 
variable. The mean fever clearance times ranged from 
3·9 days to 5·4 days, the number of clinical failures ranged 
from none to six, and the number of relapses ranged from 
one to four in these small trials.
Added value of this study
Our data augment previous ﬁ ndings, predicting that ceftriaxone 
is safe and eﬀ ective for the treatment of enteric fever and 
out-performs gatiﬂ oxacin, with only 7% of culture-positive 
patients failing treatment, and a median fever clearance time of 
2·78 days. However, our study, by contrast with the outlined 
studies, also investigated the clinical outcome in culture-negative 
patients with suspected enteric fever—in this group, gatiﬂ oxacin 
out-performed ceftriaxone with median fever clearance times of 
1·12 days and 3·03, respectively. Furthermore, our work is the ﬁ rst 
to describe the clinical implications of ﬂ uoroquinolone-resistant 
Salmonella enterica serovar Typhi.
Implications of all the available evidence
In view of the emergence of ﬂ uoroquinolone-resistant S Typhi 
in this setting and the poor eﬃ  cacy of ceftriaxone in the 
culture-negative group, we advocate better diagnostic testing 
for febrile diseases in low-income countries, and suggest that 
ﬂ uoroquinolones are no longer eﬀ ective for treatment of 
enteric fever in Nepal. 
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been given a ﬂ uoroquinolone, a third-generation 
cephalosporin, or a macrolide within the previous week. 
Patients who had received chloramphenicol, amoxicillin, 
or co-trimoxazole could be included, provided the 
treating clinician reported no clinical response. Written, 
informed consent to participate in the study was required 
from all patients. For patients younger than 18 years, we 
obtained written, informed consent from their parent or 
an adult guardian.
Randomisation and masking
We randomly assigned patients (1:1) without 
stratiﬁ cation to 7 days of treatment with either oral 
gatiﬂ oxacin (10 mg/kg) once per day or intravenous 
ceftriaxone (60 mg/kg up to a maximum of 2 g for 
patients aged 2–13 years or 2 g for patients aged 
≥14 years) once per day. The randomisation list was 
computer-generated with blocks of four and six (with 
equal probability) and maintained by a clinical trials 
pharmacist. We concealed treatment allocations inside 
opaque sealed envelopes, which were numbered 
sequentially to correspond to patient enrolment 
numbers. Envelopes were kept in a locked drawer and 
were opened in strictly numerical order by a study 
clinician (who had previously screened the patients and 
obtained consent). Treatment allocation was open-label; 
masking was not possible because of a diﬀ erence in the 
administration route of the two drugs.
Procedures
Gatiﬂ oxacin 400 mg tablets (Square Pharmaceuticals, 
Bangladesh) were weighed and cut at a dose of 10 mg/kg 
once per day. Ceftriaxone (Powercef, 1000 mg injection 
vial, Wockhardt Ltd, India), was injected slowly over 10 min 
once per day. Patients received the ﬁ rst dose (on day 1) of 
the study drug in hospital to monitor for anaphylaxis. 
Patients receiving ceftriaxone were discharged with an 
intravenous cannula in situ and had a new cannula 
inserted on day 4 of treatment. Home treatment was 
monitored by trained community medical auxiliaries 
(CMAs), as described in previous studies.14,16,17 A CMA 
visited each patient assigned to treatment twice per day for 
at least 10 days or until the patient was asymptomatic. The 
CMAs gave the drugs, and recorded drug doses, 
administration times, oral temperatures, symptoms, and 
potential adverse eﬀ ects in a standard case-record form.
We measured complete blood count, serum creatinine, 
liver-function parameters (total bilirubin, aspartate 
aminotransferase, and alanine aminotransferase), and 
serum glucose at enrolment and on day 8 of treatment. 
We did a ﬁ nger-prick test for glucose each day on days 2–7 
after randomisation, and measured random serum 
glucose on day 8, day 15, and at 1 month.
We took blood from all patients (3 mL from those aged 
<14 years; 8 mL from those aged ≥14 years) for bacterial 
culture at enrolment and on day 8 after randomisation if 
S Typhi or S Paratyphi were isolated at enrolment, or if 
their symptoms suggested a clinical relapse. We 
inoculated blood samples from adults into media-
containing tryptone soya broth and sodium polyanethol 
sulphonate, up to a total volume of 50 mL. We used 
BactecPeds Plus culture bottles (Becton Dickinson, New 
Jersey, USA) for paediatric blood samples. Culture results 
were reported for up to 7 days; positive bottles were 
subcultured onto blood, chocolate, and MacConkey agar, 
and colonies presumptive of salmonella were identiﬁ ed 
using standard biochemical tests and serotype-speciﬁ c 
antisera (Murex Biotech, Dartford, UK). We measured 
antimicrobial sensitivities by the modiﬁ ed Kirby-Bauer 
disc diﬀ usion method with zone size interpretation 
based on guidelines from the Clinical and Laboratory 
Standards Institute.20 Antimicrobial discs tested were 
Figure 1: Trial proﬁ le
Salmonella enterica Typhi or Salmonella enterica Paratyphi A were isolated from the blood of patients with 
culture-conﬁ rmed enteric fever.
725 patients assessed for trial eligibility
246 patients randomised
         122 assigned gatifloxacin
         124 assigned ceftriaxone
239 patients analysed (modified 
 intention to treat)
479 patients excluded before randomisation
 178 already taking antimicrobials
 163 refused consent
 53 did not fulfil age criteria
 6 pregnant or lactating
 64 could not arrange to be followed up
 15 other reasons
7 patients excluded after randomisation
 1 dropped out before single dose
 3 denied intravenous medication
 3 had an alternative diagnosis confirmed
 1 urinary tract infection
 1 miliary tuberculosis
 1 tuberculosis meningitis
120 assigned gatifloxacin 119 assigned ceftriaxone
62 culture-confirmed 
 enteric fever
58 culture negative 54 culture-confirmed 
 enteric fever
65 culture negative
59 patients followed 
 up until afebrile
57 patients followed 
 up until afebrile
54 patients followed 
 up until afebrile
62 patients followed 
 up until afebrile
51 patients followed 
 up at 28 days
52 patients followed 
 up at 28 days
50 patients followed 
 up at 28 days
55 patients followed 
 up at 28 days
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ceftriaxone (30 μg), ciproﬂ oxacin (5 μg), gatiﬂ oxacin 
(5 μg), and nalidixic acid (30 μg). MICs against these 
antimicrobials were measured by Etest, according to the 
manufacturer’s recommendations (BioMérieux, France). 
All patients were requested to attend a clinic at Patan 
Hospital on day 8, day 15, and 1 month, 3 months, and 
6 months after randomisation for clinical assessments 
and stool culture.
Outcomes
The primary endpoint of this trial was a composite of 
treatment failure, deﬁ ned as the occurrence of at least one 
of the following events: fever clearance time (ie, time from 
the ﬁ rst dose of a study drug until the temperature fell to 
≤37·5oC and remained there for at least 2 days) more than 
7 days after treatment initiation; the need for rescue 
treatment as judged by the treating physician (the 
recommended rescue treatment was azithromycin; 
however, any treatment other than the assigned treatment 
was acceptable); blood-culture positivity for S Typhi or 
S Paratyphi on day 8 of treatment (microbiological failure); 
culture-conﬁ rmed or syndromic enteric fever relapse 
within 28 days of treatment initiation; or development of 
any enteric fever-related complication (eg, clinically 
signiﬁ cant bleeding, a fall in the patient’s Glasgow Coma 
Score, perforation of the gastrointestinal tract, or 
admission to hospital) within 28 days after treatment 
initiation. Time to treatment failure was deﬁ ned as the 
time from the ﬁ rst dose of treatment until the date of the 
earliest failure event; patients without a failure event were 
censored on day 28 or the date of their last follow-up.
Secondary endpoints were fever clearance time only; 
time to relapse until day 28 or at any time during follow-
up; conﬁ rmed and syndromic relapse until day 28; 
conﬁ rmed or syndromic relapse at any time; and faecal 
carriage of S Typhi or S Paratyphi at 1 month, 3 months, or 
6 months after randomisation assessed in culture-positive 
patients only. We calculated fever clearance times 
electronically using temperatures recorded twice per day. 
We treated these times as interval-censored outcomes to 
show that fever clearance was known to have occurred at 
some unknown point in the interval from the last febrile 
temperature assessment until the ﬁ rst afebrile assessment. 
We treated patients without fever clearance or relapse as 
right-censored.
Safety and adverse events were assessed each day by the 
CMAs at the patient’s home, by giving a symptom 
questionnaire and simple physical examinaton. Any 
patient who had unexpected symptoms was assessed by a 
study clinician in the hospital. Each patient was also seen 
by the study clinician in the hospital on the scheduled 
follow-up days and asked about any symptoms, and a 
physical examination was undertaken to assess for 
possible adverse events.
Statistical analysis
In this study, we aimed to address the hypothesis that 
gatiﬂ oxacin was superior to ceftriaxone. On the basis of 
our previous data,17 we predicted that about 7% of 
patients with a positive culture given gatiﬂ oxacin would 
have treatment failure. To detect an increase in the risk 
of failure by 20% (from 7% to 27%) in the ceftriaxone 
group with 80% power at the two-sided 5% signiﬁ cance 
level, and allowing for a 10% loss to follow-up, we 
calculated that a sample size of 120 culture-positive 
patients (60 per treatment group) was needed. We 
assumed a culture-positive rate of at least 40%, and 
designed the trial to randomly assign 300 patients to 
treatment.
For treatment failure, we based the comparison of the 
absolute risk of treatment failure until day 28 on 
Gatiﬂ oxacin (N=120) Ceftriaxone (N=119)
N n (%) or median (IQR) N n (%) or median (IQR)
Age (years) 120 19·0 (15·0–23·0) 119 20·0 (14·0–23·5)
Sex
Male 120 99 (83%) 119 81 (68%)
Female 120 21 (18%) 119 38 (32%)
Temperature (°C) 116 38·8 (38·3–39·4) 116 38·8 (38·3–39·4)
Days of illness before enrolment 120 5·0 (4·0–6·0) 119 5·0 (4·0–7·0)
Treatment with antibiotics in past 
2 weeks
120 21 (18%) 119 17 (14%)
Previous history of typhoid 120 18 (15%) 118 19 (16%)
Family history of typhoid 120 18 (15%) 119 17 (14%)
Typhoid vaccination 119 6 (5%) 119 5 (4%)
Fever 120 120 (100%) 118 118 (100%)
Cough 115 38 (33%) 113 42 (37%)
Constipation 117 9 (8%) 116 16 (14%)
Headache 119 99 (83%) 116 108 (93%)
Diarrhoea 117 25 (21%) 116 28 (24%)
Vomiting 116 32 (28%) 116 30 (26%)
Abdominal pain 114 31 (27%) 115 27 (23%)
Anorexia 118 88 (75%) 116 80 (69%)
Nausea 116 60 (52%) 114 55 (48%)
Splenomegaly 117 0 114 2 (2%)
Hepatomegaly 117 0 114 0
Random blood glucose (mmol/L) 117 5·38 (4·77–6·11) 117 5·38 (4·94–5·88)
Creatinine (μmol/L) 116 70·72 (61·88–79·56) 114 70·72 (61·88–79·56)
Total bilirubin (μmol/L) 117 13·68 (10·26–17·10) 117 11·97 (10·26–15·39)
Leucocyte cell count (×10⁹/L) 120 6·9(4·8–7·2) 119 5·8 (4·7–7·3)
Haematocrit (%) 119 39·6 (37·0–43·0) 116 38·7 (35·8–44·0)
Platelet cell count (×10⁹/L) 120 170·0 (150·0–210·0) 119 167·0 (145·5–203·0)
AST (U/L) 117 46·0 (32·0–66·0) 116 51·5 (38·8–80·0)
ALT (U/L) 117 46·0 (30·0–63·0) 117 45·0 (33·0–63·0)
Culture positive
Salmonella Paratyphi A isolated 120 19 (16%) 119 16 (13%)
Salmonella Typhi isolated 120 43 (36%) 119 38 (32%)
No growth or culture negative 120 58 (48%) 119 65 (55%)
N refers to the number of patients with non-missing data in each group. AST=serum aspartate aminotransferase. 
ALT=serum alanine aminotransferase. 
Table 1: Baseline characteristics of the modiﬁ ed intention-to-treat population
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Kaplan-Meier estimates and corresponding standard 
errors according to Greenwood’s formula.21 We used 
survival methods for the analysis of the time to treatment 
failure, fever clearance time, and time to relapse. For the 
times to treatment failure and relapse, we used the 
Kaplan-Meier method to calculate the cumulative 
incidence of events and Cox regression models with 
treatment group as the only covariate used for 
comparison between treatment groups. For the interval-
censored fever clearance times, we used the non-
parametric maximum likelihood estimator (NPMLE) to 
estimate their distribution, and parametric Weibull 
accelerated failure time models for the estimation of 
quantiles of the fever clearance time in each group and 
for the comparison between groups.21 We based median 
(IQR) calculations of fever clearance times on models for 
each treatment group separately, and acceleration factors 
on models that included treatment as the only covariate.
We undertook all analyses for each of the three main 
analysis populations: a modiﬁ ed intention-to-treat (ITT) 
population (consisting of all randomised patients who 
received at least one dose of study treatment and did not 
have a conﬁ rmed alternative diagnosis), and the 
subpopulations with either conﬁ rmed blood-culture 
positivity, or blood-culture negativity. Treatment failure 
and fever clearance time were also assessed in predeﬁ ned 
subgroups (age <16 years; age ≥16 years; female; male; 
recruited before or after April, 2013; MIC against 
ciproﬂ oxacin <0·12 μg/mL, 0·12–2·00 μg/mL, or 
>2·00 μg/mL; MIC against gatiﬂ oxacin ≤1·00 μg/mL or 
>1·00 μg/mL; S Typhi infection; and S Paratyphi infection). 
We tested for  heterogeneity of treatment eﬀ ects between 
subgroups with a Cox regression model (for analysis of 
treatment failure) or a Weibull accelerated failure time 
model (for fever clearance times) that included an 
interaction term between the treatment and the 
subgrouping variable. We did all analyses using the 
statistical software R version 3.0.1,22 based on available 
data without imputation of missing data. The safety of 
the trial was overseen by an independent data and safety 
monitoring board. This trial was registered at 
ClinicalTrials.gov, number NCT01421693.  
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between Sept 18, 2011, and July 14, 2014, we screened 
725 patients with suspected enteric fever for enrolment 
(ﬁ gure 1). The data and safety monitoring board reviewed 
the outcome data after 100 patients, and then 200 patients, 
were randomised. At the 200-patient review, the board 
requested an additional review within 3 months of MICs 
against ciproﬂ oxacin and gatiﬂ oxacin against all bacterial 
isolates. Data from 109 culture-conﬁ rmed patients (and 
233 patients in total) were analysed at this additional 
review. A comparison of treatment failures between 
treatment groups did not cross the predeﬁ ned Haybittle-
Peto stopping boundary23 of p less than 0·001 (overall or 
in any subgroup), but the emergence of S Typhi strains 
with MICs against ciproﬂ oxacin that were 
greater than 16 μg/mL and against gatiﬂ oxacin that were 
greater than 1 μg/mL, and a signiﬁ cant diﬀ erence 
(p=0·0002 for susceptive vs resistant strains in the 
gatiﬂ oxacin group) in treatment response between 
patients with ﬂ uoroquinolone-resistant strains and those 
with susceptible strains, led the board to recommend 
stopping the trial on clinical grounds supported by data 
on the changing in-vitro susceptibility.
The trial was stopped on July 14, 2014. At this point, we 
had recruited and randomly assigned 246 eligible 
patients to treatment (including 116 patients with micro-
biologically conﬁ rmed disease; ﬁ gure 1). Seven patients 
were excluded from the ITT population—four withdrew 
consent after randomisation but before receiving the ﬁ rst 
dose of study drug, and three had an alternative 
All patients Gatiﬂ oxacin Ceftriaxone
Salmonella Typhi N=81 N=43 N=38
MIC against ciproﬂ oxacin (μg/mL) n=78 n=41 n=37
MIC 50 0·38 0·38 0·38
MIC 90 >32·00 >32·00 13·40
Range* 0·008–>32·00 0·008–>32·00 0·016–>32·00
MIC against gatiﬂ oxacin (μg/mL) n=78 n=41 n=37
MIC 50 0·125 0·125 0·125
MIC 90 2·000 2·000 1·250
Range* 0·006–3·000 0·006–3·000 0·006–3·000
MIC against ceftriaxone (μg/mL) n=78 n=41 n=37
MIC 50 0·094 0·094 0·125
MIC 90 0·190 0·190 0·190
Range* 0·032–0·640 0·032–0·250 0·047–0·640
Salmonella Paratyphi A N=35 N=19 N=16
MIC against ciproﬂ oxacin (μg/mL) n=34 n=18 n=16
MIC 50 0·500 0·625 0·500
MIC 90 0·925 1·000 0·750
Range* 0·380–1·000 0·380–1·000 0·380–1·000
MIC against gatiﬂ oxacin (μg/mL) n=34 n=18 n=16
MIC 50 0·500 0·500 0·500
MIC 90 0·750 0·575 0·750
Range* 0·380–0·750 0·380–0·750 0·380–0·750
MIC against ceftriaxone (μg/mL) n=34 n=18 n=16
MIC 50 0·125 0·125 0·125
MIC 90 0·190 0·145 0·220
Range* 0·064–0·500 0·094–0·190 0·064–0·500
n refers to the number of patients with non-missing data in each group. MIC=minimum inhibitory concentration. 
MIC 50=minimum inhibitory concentration at the 50th percentile. MIC 90=minimum inhibitory concentration at the 
90th percentile. *Range from the minimum to the maximum noted MIC. 
Table 2: Minimum inhibitory concentration of organism in the culture-conﬁ rmed population at enrolment
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diagnosis. On stopping the trial, 120 patients had received 
gatiﬂ oxacin and 119 patients had received ceftriaxone, 
totalling 239 analysed in the modiﬁ ed ITT population. 
S Typhi or S Paratyphi A was isolated from the blood of 
62 patients in the gatiﬂ oxacin group and 54 patients in 
the ceftriaxone group (ﬁ gure 1). Analyses were not 
adjusted for early stopping of the trial.
The baseline characteristics of patients were balanced 
between the two treatment groups in the modiﬁ ed 
ITT population (table 1) except for a larger proportion of 
men in the gatiﬂ oxacin group. Similar numbers of 
patients in each group had received a non-exclusion 
antimicrobial in the 2 weeks before randomisation. 
However, culture-negative patients were more likely to 
have had enteric fever previously and to report coughing, 
and had lower serum transaminase concentrations, than 
patients with blood culture-conﬁ rmed S Typhi or 
S Paratyphi A (appendix). Moreover, patients with 
S Typhi were more likely to report anorexia, nausea, and 
diarrhoea, and had a lower haematocrit compared with 
the other two patient groups.
The MICs against ciproﬂ oxacin and the study drugs 
were also balanced between the treatment groups 
(table 2). The ﬁ rst patient with a ciproﬂ oxacin-resistant 
S Typhi culture (MIC >32 μg/mL) was enrolled on 
April 30, 2013. From that date, 118 additional patients 
were recruited, 55 of whom had positive blood cultures. 
Among these, 14 (25%) of 55 patients with S Typhi 
infections with high MICs against ciproﬂ oxacin 
(12 >32 μg/mL, two 24 μg/mL) were assigned to a study 
drug; all 14 strains were also highly resistant to 
gatiﬂ oxacin (MIC ≥1·5 μg/mL).
Gatiﬂ oxacin 
(events/n [%])
Ceftriaxone 
(events/n [%])
Hazard ratio of time to 
failure (95% CI); p value
Heterogeneity 
test 
(pinteraction value)
All patients (modiﬁ ed intention-to-treat population) 18/120 (15%) 19/119 (16%) 1·04 (0·55–1·98); p=0·91
Culture-negative or culture-positive populations <0·0001
Culture negative 2/58 (3%) 15/65 (23%) 7·50 (1·71–32·80); p=0·01
Culture positive 16/62 (26%) 4/54 (7%) 0·24 (0·08–0·73); p=0·01
Pathogen (culture-conﬁ rmed population) 0·25
Salmonella Paratyphi A 1/19 (5%) 1/16 (6%) 1·13 (0·07–18·02); p=0·93
Salmonella Typhi 15/43 (35%) 3/38 (8%) 0·18 (0·05–0·62); p=0·01
Age (modiﬁ ed intention-to-treat population) 0·25
<16 years 6/32 (19%) 4/36 (11%) 0·57 (0·16–2·00); p=0·38
≥16 years 12/88 (14%) 15/83 (18%) 1·31 (0·61–2·80); p=0·48
Age (culture-conﬁ rmed population) 0·76
<16 years 6/21 (29%) 1/16 (6%) 0·19 (0·02–1·62); p=0·13
≥16 years 10/41 (24%) 3/38 (8%) 0·27 (0·07–0·98); p=0·047
Sex (modiﬁ ed intention-to-treat population) 0·52
Female 3/21 (14%) 4/38 (11%) 0·69 (0·15–3·07); p=0·62
Male 15/99 (15%) 15/81 (19%) 1·21 (0·59–2·47); p=0·61
Sex (culture-conﬁ rmed population) 0·08
Female 3/11 (27%) 0/17 0 (0–∞); p=1·00
Male 13/51 (25%) 4/37 (11%) 0·37 (0·12–1·15); p=0·09
Recruitment date (modiﬁ ed intention-to-treat population) 0·15
Before April 1, 2013 7/62 (11%) 11/59 (19%) 1·69 (0·66–4·36); p=0·28
April 1, 2013, or later 11/58 (19%) 8/60 (13%) 0·65 (0·26–1·61); p=0·35
Recruitment date (culture-conﬁ rmed population) 0·70
Before April 1, 2013 6/33 (18%) 1/28 (4%) 0·18 (0·02–1·46); p=0·11
April 1, 2013, or later 10/29 (34%) 3/26 (12%) 0·28 (0·08–1·00); p=0·05
MIC against ciproﬂ oxacin (culture-conﬁ rmed population) 0·15
<0·12 μg/mL 0/4 1/3 (33%) ∞ (0–∞); p=1·00
0·12–2·00 μg/mL 8/45 (18%) 2/46 (4%) 0·22 (0·05–1·05); p=0·06
>2·00 μg/mL* 8/10 (80%) 1/4 (25%) 0·17 (0·02–1·38); p=0·10
MIC against gatiﬂ oxacin (culture-conﬁ rmed population) 0·58
≤1 μg/mL 8/49 (16%) 3/49 (6%) 0·34 (0·09–1·28); p=0·11
>1 μg/mL 8/10 (80%) 1/4 (25%) 0·17 (0·02–1·38); p=0·10
MIC=minimum inhibitory concentration. *Among the 14 strains, two had a ciproﬂ oxacin MIC of 24 μg/mL and 12 had a ciproﬂ oxacin MIC>32 μg/mL 
Table 3: Treatment failure (primary endpoint) overall and in predeﬁ ned subgroups
See Online for appendix
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Treatment failure in the modiﬁ ed ITT population was 
similar between treatment groups: 18 (15%) of 
120 patients who received gatiﬂ oxacin had treatment 
failure, compared with 19 (16%) of 119 who received 
ceftriaxone (hazard ratio [HR] of time to failure 1·04 
[95% CI 0·55–1·98]; p=0·91 [table 3]). Details for each 
event in the composite endpoint are in the appendix. 
However, there was signiﬁ cant heterogeneity in the 
primary outcome between the subpopulations of blood 
culture-conﬁ rmed and culture-negative patients 
(pinteraction<0·0001; table 3, ﬁ gure 2). In the culture-
conﬁ rmed population, 16 (26%) of 62 patients given 
gatiﬂ oxacin had treatment failure, compared with four 
(7%) of 54 patients given ceftriaxone (HR 0·24 [95% CI 
0·08–0·73, p=0·01; table 3, absolute risks of failure in 
appendix). For the four patients with treatment failure in 
the ceftriaxone group, MICs against ceftriaxone ranged 
from 0–0·2 μg/mL, and were similar to MICs in patients 
without treatment failure. Treatment failure was 
associated with the emergence of S Typhi exhibiting 
resistance against ﬂ uoroquinolones. None of the 
subgroup analyses for culture-positive patients showed 
signiﬁ cant treatment eﬀ ect heterogeneity of the primary 
endpoint (table 3).
By contrast, in culture-negative patients, only two (3%) 
of 58 who received gatiﬂ oxacin failed treatment compared 
with 15 (23%) of 65 who received ceftriaxone (HR 7·50 
[95% CI 1·71–32·80]; p=0·01 [table 3, absolute risks of 
failure in appendix]). The most common cause of 
treatment failure in culture-negative patients treated 
with ceftriaxone was fever for more than 7 days (12 [80%] 
of 15 patients) and nine [60%] of 15 received rescue 
treatment (appendix).
In the modiﬁ ed ITT population, fever clearance times 
did not diﬀ er between the two treatment groups (table 4, 
ﬁ gure 2). Furthermore, the incidence of microbiological 
failure or syndromic relapse at any time until 6 months 
did not diﬀ er between the two treatment groups by 
day 28 or by 6 months (appendix).
We noted signiﬁ cant heterogeneity (pinteraction<0·0001) 
of the treatment eﬀ ect for fever clearance times in the 
blood culture-positive and blood culture-negative 
subgroups (table 4, ﬁ gure 2). In culture-positive 
patients, median fever clearance times were longer in 
those treated with gatiﬂ oxacin than ceftriaxone 
(p=0·001) and outcomes with gatiﬂ oxacin were worse 
for patients with a raised MIC against ciproﬂ oxacin and 
gatiﬂ oxacin (table 4). Occurrence of relapse did not 
diﬀ er between treatment groups in culture-positive 
patients (appendix). At 1-month follow-up, only two 
patients had positive stool cultures (one for S Typhi and 
one for S Paratyphi A), both in the gatiﬂ oxacin group. 
Figure 2: Time to treatment failure and fever clearance time
Time to treatment failure shown in the (A) modiﬁ ed intention to treat, (B) culture-conﬁ rmed, and (C) culture-negative populations. Fever clearance times shown in 
the (D) modiﬁ ed intention to treat, (E) culture-conﬁ rmed, and (F) culture-negative populations. Fever clearance times were interval-censored; because numbers at 
risk are not well deﬁ ned in this setting they are not shown for graphs D, E, or F. HR=hazard ratio. AF=acceleration factor. 
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We noted no positive stool cultures at 3 months or 
6 months in culture-positive patients (appendix). In 
culture-negative patients, fever clearance times were 
shorter in those treated with gatiﬂ oxacin than 
ceftriaxone (p<0·0001; table 4), but occurrences of 
relapse did not diﬀ er between treatment groups 
(appendix). 
Over the course of the trial, 122 adverse events 
occurred in the gatiﬂ oxacin group and 120 in the 
ceftriaxone group (appendix); no serious adverse events 
were reported. The most common adverse events 
reported were vomiting (in 27 [23%] of 120 patients 
receiving gatiﬂ oxacin and 17 [14%] of 119 receiving 
ceftriaxone; p=0·13), and cough (which did signiﬁ cantly 
diﬀ er between groups: in 15 [12%] patients receiving 
gatiﬂ oxacin and 29 [24%] patients receiving ceftriaxone; 
p=0·02). No adverse events were attributed to any of the 
study treatments. The frequency of dysglycaemia and 
abnormal liver-function tests did not diﬀ er between the 
treatment groups (appendix), and none of the study 
participants died.
Discussion
In patients with clinically suspected enteric fever, we 
showed that outcomes did not diﬀ er between patients 
receiving gatiﬂ oxacin and those receiving ceftriaxone. 
Gatiﬂ oxacin Ceftriaxone Acceleration factor 
(95% CI), p value
Heterogeneity 
test 
(pinteraction value) 
n Median (IQR) days n Median (IQR) days
All patients (modiﬁ ed intention-to-treat 
population)
120 2·43 (1·09–4·56) 119 2·93 (1·44–5·12) 0·89 (0·72–1·11); p=0·31
Culture-negative or culture-positive population <0·0001
Culture negative 58 1·12 (0·39–2·58) 65 3·03 (1·31–5·85) 0·44 (0·30–0·65); p<0·0001
Culture positive 62 4·21 (2·63–6·10) 54 2·78 (1·62–4·26) 1·42 (1·15–1·76); p=0·001
Pathogen (culture-conﬁ rmed population) 0·57
Salmonella Paratyphi A 19 3·68 (2·50–4·98) 16 2·24 (1·18–3·69) 1·31 (0·88–1·94); p=0·19
Salmonella Typhi 43 4·51 (2·79–6·58) 38 3·03 (1·86–4·46) 1·47 (1·15–1·88); p=0·002
Age (modiﬁ ed intention-to-treat population) 0·29
<16 years 32 3·02 (1·70–4·75) 36 2·23 (0·93–4·46) 1·08 (0·72–1·60); p=0·72
≥16 years 88 2·22 (0·92–4·45) 83 3·25 (1·70–5·41) 0·83 (0·64–1·08); p=0·16
Age (culture-conﬁ rmed population) 0·46
<16 years 21 3·82 (2·45–5·43) 16 3·04 (1·94–4·32) 1·26 (0·90–1·76); p=0·18
≥16 years 41 4·43 (2·77–6·43) 38 2·66 (1·47–4·22) 1·51 (1·15–1·97); p=0·003
Sex (modiﬁ ed intention-to-treat population) 0·99
Female 21 2·41 (1·13–4·39) 38 2·78 (1·34–4·94) 0·89 (0·56–1·41); p=0·61
Male 99 2·44 (1·09–4·59) 81 2·99 (1·48–5·20) 0·89 (0·68–1·14); p=0·35
Sex (culture-conﬁ rmed population) 0·68
Female 11 4·27 (3·12–5·47) 17 3·06 (1·93–4·41) 1·25 (0·86–1·83); p=0·25
Male 51 4·18 (2·56–6·16) 37 2·66 (1·50–4·17) 1·46 (1·13–1·89); p=0·004
Recruitment date (modiﬁ ed intention-to-treat population) 0·09
Before April 1, 2013 62 2·30 (1·10–4·09) 59 2·79 (1·16–5·55) 0·74 (0·53–1·03); p=0·08
April 1, 2013, or later 58 2·60 (1·12–5·04) 60 3·05 (1·76–4·69) 1·09 (0·82–1·45); p=0·56
Recruitment date (culture-conﬁ rmed population) 0·12
Before April 1, 2013 33 3·88 (2·63–5·26) 28 2·54 (1·31–4·27) 1·21 (0·90–1·63); p=0·22
April 1, 2013, or later 29 4·68 (2·82–6·97) 26 3·00 (1·96–4·20) 1·68 (1·26–2·23); p=0·0004
MIC against ciproﬂ oxacin (culture-conﬁ rmed population) 0·02
<0·12 μg/mL 4 2·55 (1·82–3·32) 3 4·98 (4·09–5·82) 0·58 (0·35–0·94); p=0·028
0·12–2·00 μg/mL 45 3·88 (2·67–5·21) 46 2·63 (1·49–4·12) 1·24 (0·99–1·56); p=0·06
>2·00 μg/mL* 10 8·20 (5·99–10·50) 4 3·66 (2·84–4·46) 2·36 (1·58–3·51); p=<0·0001
MIC against gatiﬂ oxacin (culture-conﬁ rmed population) 0·049
≤1·00 μg/mL 49 3·76 (2·56–5·08) 49 2·75 (1·58–4·27) 1·17 (0·94–1·45); p=0·15
>1·00 μg/mL 10 8·20 (5·99–10·50) 4 3·66 (2·84–4·46) 2·36 (1·58–3·51); p<0·0001
Percentages not added to this table because the denominators for populations change and are not clearly speciﬁ ed. MIC=minimum inhibitory concentration.  *Among the 14 strains, two had a ciproﬂ oxacin MIC 
of 24 μg/mL and 12 had an MIC >32 μg/mL.
Table 4: Fever clearance time (secondary endpoint) overall and in predeﬁ ned subgroups
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However, patients with blood culture-conﬁ rmed enteric 
fever fared less well when given gatiﬂ oxacin, as 
suggested by an increased likelihood of treatment failure 
and protracted fever clearance times. This ﬁ nding was 
apparent only in the last year of recruitment into the trial 
as S Typhi strains with high-level resistance to 
ciproﬂ oxacin and gatiﬂ oxacin (MICs >16 μg/mL and 
>1 μg/mL, respectively) emerged during the study, 
leading to the trial being stopped in July, 2014.
The data resulting from this trial contradict our 
hypothesis, because before the emergence of 
ﬂ uoroquinolone-resistant S Typhi in Nepal, we had 
shown in a series of clinical trials (done between 2004 
and 2011) that gatiﬂ oxacin was both a safe and eﬀ ective 
treatment for uncomplicated enteric fever.14,16,17 This 
antimicrobial has provided good clinical outcomes 
despite the continuing isolation of S Typhi and 
S Paratyphi A organisms showing reduced susceptibility 
against ciproﬂ oxacin (MICs from 0·1 μg/mL–1 μg/mL).7,24 
Although the treatment failure results with gatiﬂ oxacin 
in our study are based on data from a few patients, these 
ﬁ ndings are highly consistent with the results of larger 
numbers for the secondary endpoint of fever clearance, 
which lend support to the credibility of our results. 
Generally, we still regard gatiﬂ oxacin as a safe drug for 
use in this setting since we have no evidence for an 
increased risk of dysglycaemia or hepatitis. However, 
our new data suggest that the eﬃ  cacy of gatiﬂ oxacin 
(and older-generation ﬂ uoroquinolones) for the 
treatment of enteric fever in Nepal is now compromised 
by the emergence of high-level ﬂ uoroquinolone-
resistant S Typhi. As a result, we no longer advocate 
gatiﬂ oxacin as a treatment for enteric fever in Nepal. 
Despite being a two-centre study in Kathmandu, our 
ﬁ ndings raise substantial questions regarding the use of 
ﬂ uoro quinolones in south Asia and other endemic 
regions for treating enteric fever. Genomic data has 
shown that strains with reduced susceptibility to 
ﬂ uoroquinolones are now globally dominant.25 The 
process of resistance development against the 
ﬂ uoroquinolones is a stepwise process; mutations are 
sequentially acquired in the target genes, thus 
determining higher MICs.7 Data obtained from in-vitro 
experiments suggest that strains with ﬂ uoroquinolone-
resistance-associated mutations might actually have a 
selective advantage over wild-type strains.26 Fluoro-
quinolone resistance is clearly increasing, not only in 
Nepal, but also in neighbouring areas and other parts of 
the world where resources are low.24 Therefore in view of 
this combination of evidence, we predict a short window 
before the international emergence of S Typhi, and 
potentially S Paratyphi A, strains with high-level 
ﬂ uoroquinolone resistance, thus rendering this 
important group of antimicrobials globally ineﬀ ective 
for enteric fever. Conversely, the outcomes for 
ceftriaxone-treated, culture-positive patients were good, 
with short fever clearance times and few relapses. The 
optimum duration of ceftriaxone treatment is not clearly 
deﬁ ned; in WHO guidelines, it is recommended for 
10–14 days,6,19 but our data lend support to a 7-day 
treatment course for patients with uncomplicated 
enteric fever in an endemic setting.
Alongside antimicrobial-resistant S Typhi, our clinical 
ﬁ ndings pose an additional clinical and public health 
challenge regarding ceftriaxone treatment. In patients 
with a negative blood-culture result, the absolute risk of 
treatment failure was 0·24 in the ceftriaxone group versus 
0·04 in the gatiﬂ oxacin group. Furthermore, the median 
fever clearance times in this group were 3·03 days in the 
ceftriaxone group, versus 1·12 days in the gatiﬂ oxacin 
group. These contrasting outcomes for ceftriaxone in the 
two predeﬁ ned patient populations were not predicted 
and previous similar data from other enteric fever trials 
are scarce. The reason for this shortage of data is because 
the results of patients enrolled in enteric fever trials who 
did not have a positive blood culture were, until recently, 
not reported. From a small ceftriaxone study11 done in 
Vietnamese patients with enteric fever, the investigators 
reported that two of the six culture-negative patients given 
ceftriaxone failed treatment, but responded to rescue 
treatment with oﬂ oxacin. Only four randomised trials for 
enteric fever14–17 did an intention-to-treat analysis and 
incorporated an analysis for the blood culture-negative 
patients. In these trials, culture-negative patients given 
gatiﬂ oxacin, oﬂ oxacin, or azithromycin achieved similar 
(or better) outcomes than those reported in blood culture-
conﬁ rmed patients with enteric fever.
Better clinical outcomes in patients with syndromic 
enteric fever but with a negative blood-culture result 
might be attributed to the low sensitivity of blood-
culture tests (estimated to be 50–60%)5 and the 
possibility of fewer bacteria in the bloodstream, 
corresponding with less severe disease. We do not 
know how many culture-negative patients actually had 
enteric fever in our study; some might have had 
alternative bacterial infections. Our previous study27 
examined archived blood samples from 765 adults 
presenting at Patan Hospital, Nepal, with 
undiﬀ erentiated febrile illness in 2001. 50 (7%) patients 
had Rickettsia typhi (murine typhus) DNA detected by 
PCR ampliﬁ cation. Furthermore, we investigated the 
infectious cause of culture-negative patients enrolled 
into one of our other enteric fever trials in Nepal and 
noted serological evidence of murine typhus in 21 
(22%) of 96 blood culture-negative patients, with 12 
(57%) of 21 testing positive for R typhi with PCR 
ampliﬁ cation.28 Thus, we surmise that a substantial 
proportion of culture-negative patients with suspected 
enteric fever in Nepal might actually have other 
bacterial infections, included those caused by the 
rickettsiaceae. Ceftriaxone is not regarded as an 
eﬀ ective treatment for murine typhus and other 
rickettsial illnesses, whereas ﬂ uoroquinolones do seem 
to have clinical activity against these pathogens.28 
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However, no rapid diagnostic tests are available that can 
accurately diﬀ erentiate between rickettsial infections, 
enteric fever, or indeed any bacteraemia, and inform 
patient management in a timely manner. Without such 
a test, we suggest that a more pragmatic approach 
would be to combine ceftriaxone with doxycycline for 
patients without a positive blood culture who do not 
respond to ceftriaxone monotherapy. 
In conclusion, the results of our trial underline 
two substantial problems for patients with enteric fever. 
First, the continued development of antimicrobial 
resistance in the pathogens causing the disease; second, 
the absence of point-of-care diagnostic tests for febrile 
diseases in low-income settings.29 We have shown that 
high-level ﬂ uoroquinolone-resistant S Typhi is now 
likely to be endemic in Nepal and suggest that ﬂ uoro-
quinolones—even the fourth-generation ﬂ uoro-
quinolone gatiﬂ oxacin—cannot be recommended as 
empirical therapy for enteric fever in this setting. 
Azithromycin and ceftriaxone are alternative options, 
although sporadic cases of resistance have been reported, 
and data comparing in-vitro azithromycin susceptibility 
against clinical outcomes are poor.30,31 Additionally, under 
our study conditions, ceftriaxone was suboptimum in a 
large proportion of culture-negative patients with 
suspected enteric fever, which further emphasises the 
need for diagnostic tests for enteric fever and other 
common febrile diseases. Since antimicrobials, 
speciﬁ cally ﬂ uoroquinolones, are one of the only 
routinely used control measures for enteric fever, 
eﬀ ective surveillance programmes, the assessment of 
novel diagnostics, new treatment options, and the use of 
existing vaccines and development of next-generation 
vaccines are now a greater priority than ever.
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